Fate Therapeutics (FATE) Environmental, Social & Governance (ESG) Data

The following proposals were submitted to the stockholders at the Annual Meeting held on June 9, 2022:

(i) The election of three Class III Directors, as nominated by the Board of Directors, to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified;

(ii) The ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022;

(iii) A non-binding advisory vote to approve the compensation of the Company’s named executive officers as set forth in the Proxy Statement; and

(iv) A vote to approve the 2022 Plan.

The proposals are described in detail in the Proxy Statement.

The number of shares of common stock entitled to vote at the Annual Meeting was 96,584,746. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 90,212,605. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and all director nominees were elected.

The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

(a) Election of Class III Directors.


There were 5,466,226 broker non-votes regarding the election of directors.

(b) Ratification of Auditors.

Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the voting included 90,113,935 votes for 69,335 votes against, and 29,335 votes abstained.

There were zero broker non-votes regarding this proposal.

(c) Non-binding Advisory Vote on Compensation of Named Executive Officers.


There were 5,466,226 broker non-votes regarding this proposal.

(d) Approval of the 2022 Plan


There were 5,466,226 broker non-votes regarding this proposal.